GSK-209762/147 (MeMuRu-147)

Phase IV open study to assess the safety, reactogenicity and immunogenicity of GlaxoSmithKline (GSK)Biologicals live attenuated Measles-Mumps-Rubella (MMR) vaccine when given to healthy children at the age of 12 to 18months in Singapore.
Measles, Mumps, Rubella Vaccine
209762/147 (MeMuRu-147)
Measles; Mumps; Rubella
Phase 4
An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.
June 2015